Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Immunovant, Inc. (Nasdaq: IMVT) appointed Michael Elliott, MBBS, PhD as Chief Scientific Officer. He brings over 23 years of R&D experience, including 17 years at Johnson & Johnson, where he led the development of innovative immunology products. Elliott will oversee the advancement of IMVT-1401, a novel antibody treatment for autoimmune diseases. The company is currently in a productive phase with three programs in Phase 2. CEO Pete Salzmann highlighted Elliott's expertise in identifying best-in-class opportunities, vital for the company’s growth.
Immunovant, Inc. (Nasdaq: IMVT) reported its financial results for the fiscal first quarter ending June 30, 2020, revealing a net loss of $26.7 million, up from $20.1 million a year prior. Cash reserves stood at approximately $280.3 million. Research and development (R&D) expenses decreased by $1.6 million to $16.9 million; however, adjusting for a one-time milestone payment in the prior year, R&D expenses actually increased by $8.5 million due to higher clinical trial costs. General and administrative (G&A) expenses surged by $8.1 million to $9.7 million, attributed to rising personnel costs and legal fees.
Immunovant, Inc. (Nasdaq: IMVT) announced that warrant holders have until June 15, 2020, to exercise 11.5 million outstanding warrants, potentially raising $66.125 million at a price of $11.50 per share. The warrants are subject to mandatory redemption if its stock price stays above $16.50 for 20 trading days. Additionally, Immunovant is triggering the issuance of 10 million shares to former shareholders after meeting specific price conditions. The company remains focused on developing treatments for autoimmune diseases.